IMMX

Immix Biopharma, Inc. (IMMX) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR-T) cell therapies, primarily for relapsed/refractory AL Amyloidosis. The Company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of May 6, 2025, there were 27,877,293 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $788,536 compared to Q1 2024. This improvement was primarily driven by a significant reduction in reported R&D expenses.
• R&D Expense Decrease: R&D expenses dropped by $1,273,595. Management attributes this decrease largely to $1.65 million in grant reimbursements from the California Institute for Regenerative Medicine (CIRM), which are recorded as an offset to R&D expenses. This was partially offset by increased costs for clinical trials and license fees.
• G&A Expense Increase: G&A expenses increased by $366,387, driven by higher compensation costs ($396,200) due to hiring additional employees, slightly offset by decreases in investor relations and professional services.
• Interest Income Decline: Interest income fell to $150,219 from $267,908 in the prior year due to lower average cash balances during the period.
• Cash Position: Cash and cash equivalents decreased by $1.76 million during the quarter, reflecting the net cash burn from operations and investing activities, with no financing cash inflows in Q1 2025.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes that existing cash ($15.9 million) combined with expected disbursements from the $8 million CIRM grant will fund operations for at least the next 12 months. However, the Company expects to require additional capital beyond this period to continue planned operations and commercialization efforts.
• CIRM Grant: The Company received $1.7 million in grant reimbursements during Q1 2025. As of April 2025, total reimbursements received under the agreement reached $3.6 million. The grant is milestone-based and contingent on patient enrollment and compliance.
• Clinical Progress: The lead candidate, NXC-201, is in Phase 1b/2 trials (NEXICART-2 in the U.S. and NEXICART-1 ex-U.S.). As of May 2025, 6 patients have been treated in the U.S. trial and 16 in the ex-U.S. trial. Recent data presented at the ASH meeting showed high response rates.
• Internal Controls: The Company disclosed a material weakness in internal control over financial reporting due to a lack of segregation of duties and formal processes, attributed to its small size. Management is working to remediate this weakness.
• Risk Factors: Key risks include the need for substantial additional capital, the uncertainty of clinical trial results, dependence on third-party manufacturers, and the potential for the CIRM grant to be suspended if milestones are not met.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the next capital raise, given the 12-month liquidity horizon and the milestone-dependent nature of the CIRM grant.
• Grant Compliance: Monitor patient enrollment rates in the NEXICART trials to ensure continued eligibility for CIRM funding.
• Internal Controls: Review future filings for updates on the remediation of the material weakness in internal controls over financial reporting.
• License Obligations: Note the upcoming $1.5 million upfront license fee payment due to HADASIT and BIRAD by April 30, 2025, under the First Amendment to the Research and License Agreement.
• Stock Issuances: Track the issuance of restricted stock for investor relations services, which occurred in Q1 2025 and subsequent to the quarter-end, potentially impacting dilution.